New Weight-Loss shot shows promise in early trial
NCT ID NCT06118021
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tested an investigational drug called HS-20094 in 200 overweight or obese adults. Participants received either the drug or a placebo injection over several weeks. The main goal was to see how much weight they lost and whether the drug was safe.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- HS-20094 injection
- What this could lead to
- If successful, this could point toward a new medication to help people with obesity lose weight.
- What could go wrong
- This is an early Phase 2 trial with only 200 participants, so results may not apply to everyone. Side effects are possible, and the drug may not prove effective enough for further development.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
200 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Aug 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female subjects,18-65 years of age at the time of signing informed consent. 2. BMI≥28.0kg/m2 or 24≤BMI\<28.0 kg/ m2 with at least 1 weight-related comorbidity at screening visit. 3. Diet and exercise control for at least 3 months before screening visit,and less than 5 kg self-reported change within the last 3 months. Exclusion Criteria: * 1\. Presence of-clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit. 2\. poor-controlled hypertension. 3. PHQ-9 score≥15. 4. Medical history or illness that affects your weight. 5. Use of any medication or treatment that may have caused significant weight change within 3 months. 6\. History of bariatric surgery. 7. History of diabetes. 8. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening. 9\. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening. 10\. Any organ-system malignancies developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix. 11\. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness. 12\. History of alcohol and/or substance abuse or drug abuse within 1 year prior to screening. 13\. Participation in other clinical trials for any weight-loss indication within 3 months prior to screening, or participation in other clinical trials for any drug or medical device within 1 month prior to screening. 14\. Known or suspected hypersensitivity to trial product(s)or related products. 15. Female who is pregnant,breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method. 16\. Researchers and relevant staff of the research Centre or other people directly involved in the implementation of the programme,and their immediate family members. 17\. In the judgment of the investigator,there are circumstances that affect the safety of the subject or any other interference with the evaluation of the test results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Overweight and obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150001, China
-
the Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can cottonseed oil improve cholesterol? trial tests common cooking oil against similar blends
- Can Weight-Loss surgery weaken protein digestion in older adults?
- Can pole walking boost heart fitness in diabetic patients?
- Weight loss after cancer: a new program aims to help survivors
- Amino acid may shield aging muscles during dieting
- AI-Powered coaching: could tailored texts boost weight loss?